Evidence map›Paper›PMID 28737960›Full record

ArticleAmerican journal of respiratory and critical care medicine2017

Optimization and Interpretation of Serial QuantiFERON Testing to Measure Acquisition of Mycobacterium tuberculosis Infection.

Elisa Nemes, Virginie Rozot, Hennie Geldenhuys, Nicole Bilek, Simbarashe Mabwe, Deborah Abrahams, Lebohang Makhethe, Mzwandile Erasmus, Alana Keyser, Asma Toefy and 15 more

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in American journal of respiratory and critical care medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03767946 (MTBVAC in Newborns), which is not on this map. Cited by 91 papers.

0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed
12.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03767946 completednot on this mapstarted 2018, after this paper: background citation

MTBVAC in Newborns: Epidemiological Study In Tuberculosis-Endemic Regions of Sub-Saharan Africa

TypeobservationalSponsorBiomedical Research Center EPLSRan2018 to 2022Enrolled500ConditionsTuberculosisArmsQuantiferon Gold Plus Test
3 · Its place in the literature

Who cites it

91 citing papers in PubMed, 165 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Observational
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

31 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors at 5 institutions in 4 countries.

Elisa Nemes1 South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and.ORCID 0000-0003-1662-4961
Virginie Rozot1 South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and.ORCID 0000-0001-9757-1501
Hennie Geldenhuys1 South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and.
Nicole Bilek1 South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and.
Simbarashe Mabwe1 South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and.
Deborah Abrahams1 South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and.
Lebohang Makhethe1 South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and.
Mzwandile Erasmus1 South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and.
Alana Keyser1 South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and.
Asma Toefy1 South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and.
Yolundi Cloete1 South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and.
Frances Ratangee1 South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and.
Thomas Blauenfeldt3 Statens Serum Institut, Copenhagen, Denmark.
Morten Ruhwald3 Statens Serum Institut, Copenhagen, Denmark.
Gerhard Walzl4 South Africa Department of Science and Technology-National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Bronwyn Smith4 South Africa Department of Science and Technology-National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Andre G Loxton4 South Africa Department of Science and Technology-National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Willem A Hanekom1 South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and.
Jason R Andrews5 Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, California; and.
Maria D Lempicki6 AERAS, Rockville, Maryland.
Ruth Ellis6 AERAS, Rockville, Maryland.
Ann M Ginsberg6 AERAS, Rockville, Maryland.
Mark Hatherill1 South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and.
Thomas J Scriba1 South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and.ORCID 0000-0002-0641-1359
C-040-404 Study Team and the Adolescent Cohort Study Team
University of Cape Town · ZAAeras · USSouth African Medical Research Council · ZAStatens Serum Institut · DKStanford University · US

Funding

Biology and Biosignatures of Anti-Tuberculosis Treatment ResponseU01AI115619 · NIAID · COLORADO STATE UNIVERSITY · PI BELISLE, JOHN T · 2015 to 2019
$3.1M
Network Models for Evaluating HIV-associated MDR TB transmission and controlK01AI104411 · NIAID · STANFORD UNIVERSITY · PI ANDREWS, JASON RANDOLPH · 2013 to 2016
$549k
NIAID NIH HHS K01 AI104411NIAID NIH HHS U01 AI115619
6 · The paper itself

Abstract

rationaleConversion from a negative to positive QuantiFERON-TB test is indicative of Mycobacterium tuberculosis (Mtb) infection, which predisposes individuals to tuberculosis disease. Interpretation of serial tests is confounded by immunological and technical variability.

objectivesTo improve the consistency of serial QuantiFERON-TB testing algorithms and provide a data-driven definition of conversion.

methodsSources of QuantiFERON-TB variability were assessed, and optimal procedures were identified. Distributions of IFN-γ response levels were analyzed in healthy adolescents, Mtb-unexposed control subjects, and patients with pulmonary tuberculosis. MEASUREMENTS AND MAIN

resultsIndividuals with no known Mtb exposure had IFN-γ values less than 0.2 IU/ml. Among individuals with IFN-γ values less than 0.2 IU/ml, 0.2-0.34 IU/ml, 0.35-0.7 IU/ml, and greater than 0.7 IU/ml, tuberculin skin test positivity results were 15%, 53%, 66%, and 91% (P < 0.005), respectively. Together, these findings suggest that values less than 0.2 IU/ml were true negatives. In short-term serial testing, "uncertain" conversions, with at least one value within the uncertainty zone (0.2-0.7 IU/ml), were partly explained by technical assay variability. Individuals who had a change in QuantiFERON-TB IFN-γ values from less than 0.2 to greater than 0.7 IU/ml had 10-fold higher tuberculosis incidence rates than those who maintained values less than 0.2 IU/ml over 2 years (P = 0.0003). By contrast, "uncertain" converters were not at higher risk than nonconverters (P = 0.229). Eighty-seven percent of patients with active tuberculosis had IFN-γ values greater than 0.7 IU/ml, suggesting that these values are consistent with established Mtb infection.

conclusionsImplementation of optimized procedures and a more rigorous QuantiFERON-TB conversion definition (an increase from IFN-γ <0.2 to >0.7 IU/ml) would allow more definitive detection of recent Mtb infection and potentially improve identification of those more likely to develop disease.

Indexed as

AdolescentAdultFemaleHumansInterferon-gammaMaleMycobacterium tuberculosisReproducibility of ResultsTuberculin TestTuberculosis, PulmonaryInterferon-gammaconversionIFN-γ release assayQuantiFERONtuberculosisvariability

Identifiers

PMID28737960
PMCPMC5620669
OpenAlexW2739452922

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.